Anti-CdtB IgA

Cytolethal distending toxin B (CdtB) is a bacterial toxin that disrupts intestinal barriers and triggers inflammation. Anti-CdtB IgA is an antibody produced in response to CdtB and is associated with post-infectious irritable bowel syndrome (PI-IBS), particularly the diarrhea-predominant subtype (IBS-D). 

Elevated Anti-CdtB IgA levels can help identify patients with PI-IBS, though its diagnostic value is still evolving, especially in differentiating PI-IBS from other gastrointestinal conditions. 

What is CdtB?

Cytolethal distending toxin B (CdtB) is a bacterial virulence factor produced by Gram-negative pathogens, such as Campylobacter jejuni, Salmonella, E. coli, and Shigella, which are associated with gastrointestinal infections. 

CdtB disrupts epithelial barriers, triggers inflammatory responses, and suppresses immunity, contributing to persistent infections. 

What is Anti-CdtB IgA?

Anti-CdtB IgA is an antibody produced in response to cytolethal distending toxin B (CdtB), a toxin found in several gastrointestinal pathogens.

These antibodies are most commonly associated with post-infectious irritable bowel syndrome (PI-IBS), particularly diarrhea-predominant IBS (IBS-D), where they form due to molecular mimicry between CdtB and the protein vinculin, which is essential for gut motility. 

Clinically, the presence of anti-CdtB IgA antibodies can help identify patients with PI-IBS, as these antibodies are elevated in affected individuals compared to healthy controls. 

However, their diagnostic value is limited in differentiating IBS from other gastrointestinal conditions, such as inflammatory bowel disease (IBD), and their sensitivity and specificity can vary by geographic region based on the prevalence of CdtB-expressing pathogens. 

While not yet a definitive diagnostic tool, anti-CdtB IgA antibodies remain a promising biomarker for identifying IBS related to past infections and may play a larger role in future diagnostic strategies as research progresses.

What is the Anti-CdtB IgA-Vinculin Connection?

In post-infectious conditions, particularly after bacterial gastroenteritis, antibodies against CdtB may be produced and cross-react with vinculin, a protein involved in gut motility. 

This interaction can damage intestinal cells, leading to conditions such as irritable bowel syndrome (IBS), especially the diarrhea-predominant subtype (IBS-D). Additionally, CdtB has been implicated in functional dyspepsia (FD), suggesting a potential link between post-infectious FD and IBS. 

Who Should Get Tested for Anti-CdtB IgA?

The following individuals may benefit from anti-CdtB IgA antibody testing:

Patients with Chronic Digestive Symptoms

Anti-CdtB IgA testing can provide valuable insight for individuals suffering from persistent digestive issues such as bloating, diarrhea, constipation, and abdominal pain after a bacterial infection. It may be particularly helpful for patients with symptoms that don’t resolve even after the acute infection phase has passed.

Individuals with Suspected SIBO

CdtB, produced by pathogens including Campylobacter jejuni, has been linked to developing small intestinal bacterial overgrowth (SIBO) by impairing gastrointestinal motility and fostering bacterial overgrowth. 

Testing for anti-CdtB IgA antibodies may help identify individuals at risk for SIBO, particularly in those with a history of acute gastroenteritis or IBS symptoms.

At-Risk Populations

People who frequently experience foodborne illnesses or have a history of antibiotic use may be at higher risk for developing bacterial overgrowth or PI-IBS. 

Additionally, individuals with autoimmune diseases may be more susceptible to gastrointestinal complications, making Anti-CdtB IgA testing a consideration for these patients.

Healthcare Providers Diagnosing Functional GI Disorders

Anti-CdtB IgA testing can be a useful tool for clinicians managing functional GI disorders. By suggesting PI-IBS or SIBO, anti-CdtB IgA testing enables more accurate and targeted diagnostic testing and treatment plans.

Test Procedure and Interpretation

The following section discusses the testing procedure for anti-CdtB IgA antibodies:

Testing Procedure and Preparation Requirements

Anti-CdtB IgA is typically measured through blood tests, such as ELISA or ImmunoCAP. A blood sample is collected, requiring a venipuncture, and the serum is analyzed to detect the presence of the antibody. 

No special preparation is usually required from the patient, although the sample must be processed and stored correctly to ensure accurate results.

Normal Reference Ranges

Always consult with the laboratory company used to determine appropriate reference ranges. 

In healthy individuals, Anti-CdtB IgA levels are typically low or undetectable. 

Clinical Implications of Elevated Levels

High Anti-CdtB IgA levels indicate an immune response to CdtB-producing bacteria, suggesting a post-infectious GI disorder such as PI-IBS. These results should prompt further investigation and targeted treatment to address underlying gut dysfunction.

Clinical Implications of Decreased Levels

Decreased or negative Anti-CdtB IgA levels are generally consistent with a lack of bacterial infection or immune response related to PI-IBS. These results often suggest other potential diagnoses, such as non-infectious IBS or celiac disease, and additional testing may be required.

Order Testing for Gastrointestinal Infections

Click here to compare testing options and order testing to assess for gastrointestinal pathogens.